Scientists for the first time have used CRISPR gene editing to halt the progression of Duchenne muscular dystrophy (DMD) in a large mammal, according to a study by UT Southwestern that provides a strong indication that a lifesaving treatment may be in the pipeline.
The research published in Science documents unprecedented improvement in the muscle fibers of dogs with DMD – the most common fatal genetic disease in children, caused by a mutation that inhibits the production of dystrophin, a protein critical for muscle function.
Researchers used a single-cut gene-editing technique to restore dystrophin in muscle and heart tissue by up to 92 percent of normal levels. Scientists have estimated a 15 percent threshold is needed to significantly help patients.
“Children with DMD often die either because their heart loses the strength to pump, or their diaphragm becomes too weak to breathe,” said Dr. Eric Olson, Director of UT Southwestern’s Hamon Center for Regenerative Science and Medicine. “This encouraging level of dystrophin expression would hopefully prevent that from happening.”
DMD, which affects one in 5,000 boys, leads to muscle and heart failure, and premature death by the early 30s. Patients are forced into wheelchairs as their muscles degenerate and eventually onto respirators as their diaphragms weaken. No effective treatment exists, though scientists have known for decades that a defect in the dystrophingene causes the condition.
The Science study establishes the proof-of-concept for single-cut gene editing in dystrophic muscle and represents a major step toward a clinical trial. Already Dr. Olson’s team has corrected DMD mutations in mice and human cells by making single cuts at strategic points of the mutated DNA.
The latest research applied the same technique in four dogs that shared the type of mutation most commonly seen in DMD patients. Scientists used a harmless virus called adeno-associated virus (AAV) to deliver CRISPR gene-editing components to exon 51, one of the 79 exons that comprise the dystrophin gene.
CRISPR edited the exon, and within several weeks the missing protein was restored in muscle tissue throughout the body, including 92 percent correction in the heart and 58 percent in the diaphragm, the main muscle needed for breathing.
“Our strategy is different from other therapeutic approaches for DMD because it edits the mutation that causes the disease and restores normal expression of the repaired dystrophin,” said Dr. Leonela Amoasii, lead author of the study and Assistant Instructor of Molecular Biology in Dr. Olson’s lab. “But we have more to do before we can use this clinically.”
The lab will next conduct longer-term studies to measure whether the dystrophin levels remain stable and to ensure the gene edits do not have adverse side effects.
Dr. Olson hopes the next step beyond dogs is a clinical trial, which would be among several that UT Southwestern’s gene therapy center aims to launch in the coming years to address numerous deadly childhood diseases.
In the meantime, Dr. Olson’s recent work has spawned a biotechnology company, Exonics Therapeutics Inc., which is working to further optimize and bring this technology to the clinic. Exonics intends to extend the approach to additional DMD mutations, as well as other neuromuscular diseases. Exonics has licensed the technology from UT Southwestern.
Learn more: CRISPR halts Duchenne muscular dystrophy progression in dogs
The Latest on: Duchenne muscular dystrophy
[google_news title=”” keyword=”Duchenne muscular dystrophy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Duchenne muscular dystrophy
- New type of muscular dystrophy discovered after girl’s diagnosison April 30, 2024 at 12:14 pm
An new type of muscular dystrophy that's caused by inherited mutations in the SNUPN gene results in symptoms of muscle weakness before age 2.
- Virtual Reality and Biofeedback Training Appear Effective for DMD, BMD Rehabilitationon April 29, 2024 at 11:57 am
A recent study suggests virtual reality and biofeedback training may be feasible and effective for patients with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).
- Young boy with Muscular Dystrophy gets surprise from Dothan Police on birthdayon April 29, 2024 at 10:47 am
A young boy turning six this past weekend got a special surprise from the boys in blue. Kace Perez was diagnosed with Duchenne Muscular Dystrophy in 2023. The National Library of Medicine describes ...
- Parent Project Muscular Dystrophy Awards $250,000 to Support Clinical Research Network for Duchenne Babies Identified by Newborn Screeningon April 29, 2024 at 6:59 am
Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), is excited to announce a $250,000 award to Bo Hoon Lee, MD, from the ...
- Duchenne Muscular Dystrophy: the global clinical trials landscape 2024on April 29, 2024 at 4:02 am
Affecting muscle and skeletal strength, this rare genetic disorder impacts thousands of men worldwide. Innovative new genetic therapies in development across the globe are improving the quality of ...
- Patients With DMD Receiving Eteplirsen Show Prolonged Survival, Study Findson April 25, 2024 at 2:03 pm
The study provides evidence of survival benefits among patients with Duchenne muscular dystrophy (DMD) receiving eteplirsen compared with the natural history of the condition.
- Glucocorticoid use can aid breathing ability in Duchenne adults: Studyon April 23, 2024 at 8:28 am
Glucocorticoid use was seen to help maintain breathing ability and arm function in adults in the late stages of Duchenne muscular dystrophy.
- My son's smile gives me hope for Duchenne muscular dystrophy. A new law could help otherson April 23, 2024 at 6:01 am
Finally, when we were approved for evaluation, we received a devastating diagnosis: Duchenne muscular dystrophy. Duchenne is a rare, progressive disorder in which muscle cells are in a constant ...
- My son's smile gives me hope for Duchenne muscular dystrophy. A new law could help otherson April 23, 2024 at 5:01 am
Opinion: Newborn testing can give families a head start on giving a child with the degenerative muscular disease a shot at the best outcome in life.
- Ohio to be first state in the nation to mandate newborn screening for Duchenne Muscular Dystrophyon April 22, 2024 at 1:56 pm
Adding DMD to the list of screenings newborns receive ensures that parents will be able to start initiating care early for children who are diagnosed with this condition said Governor DeWine ...
via Bing News